A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin.

Trial Profile

A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2014

At a glance

  • Drugs Glutathione/inosine (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cellectar Biosciences
  • Most Recent Events

    • 11 Feb 2014 Novelos Therapeutics now known as Cellectar Biosciences
    • 12 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 Mar 2010 Status changed from not yet recruiting to recruiting, according to a media release from Novelos Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top